Home LiteratureArticle Details
PMID: 12805431 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences.

Journal of virology ·Vol. 77 ·No. 13 ·2003-07-00 ·Pages 7330-40

Altfeld M, Addo MM, Shankarappa R, Lee PK, Allen TM, Yu XG, Rathod A, Harlow J, O'Sullivan K, Johnston MN, Goulder PJ, Mullins JI, Rosenberg ES, Brander C, Korber B, Walker BD

Abstract

The antigenic diversity of human immunodeficiency virus type 1 (HIV-1) represents a significant challenge for vaccine design as well as the comprehensive assessment of HIV-1-specific immune responses in infected persons. In this study we assessed the impact of antigen variability on the characterization of HIV-1-specific T-cell responses by using an HIV-1 database to determine the sequence variability at each position in all expressed HIV-1 proteins and a comprehensive data set of CD8 T-cell responses to a reference strain of HIV-1 in infected persons. Gamma interferon Elispot analysis of HIV-1 clade B-specific T-cell responses to 504 overlapping peptides spanning the entire expressed HIV-1 genome derived from 57 infected subjects demonstrated that the average amino acid variability within a peptide (entropy) was inversely correlated to the measured frequency at which the peptide was recognized (P = 6 x 10(-7)). Subsequent studies in six persons to assess T-cell responses against p24 Gag, Tat, and Vpr peptides based on autologous virus sequences demonstrated that 29% (12 of 42) of targeted peptides were only detected with peptides representing the autologous virus strain compared to the HIV-1 clade B consensus sequence. The use of autologous peptides also allowed the detection of significantly stronger HIV-1-specific T-cell responses in the more variable regulatory and accessory HIV-1 proteins Tat and Vpr (P = 0.007). Taken together, these data indicate that accurate assessment of T-cell responses directed against the more variable regulatory and accessory HIV-1 proteins requires reagents based on autologous virus sequences. They also demonstrate that CD8 T-cell responses to the variable HIV-1 proteins are more common than previously reported.

MeSH Terms
Amino Acid Sequence CD8-Positive T-Lymphocytes/immunology Flow Cytometry HIV Infections/immunology HIV-1/immunology Humans Immunity, Cellular Molecular Sequence Data Peptides/chemistry Sequence Homology, Amino Acid Viral Proteins/chemistry,immunology
Chemicals
Peptides Viral Proteins
Authors & Affiliations
16 authors, click to expand affiliations / ORCID
Altfeld Marcus
Partners AIDS Research Center and Infectious Disease Unit, Massachusetts General Hospital, and Division of AIDS, Harvard Medical School, Boston, Massachusetts, USA.
Addo Marylyn M
Shankarappa Raj
Lee Paul K
Allen Todd M
Yu Xu G
Rathod Almas
Harlow Jason
O'Sullivan Kristin
Johnston Mary N
Goulder Philip J R
Mullins James I
Rosenberg Eric S
Brander Christian
Korber Bette
Walker Bruce D
References (50)
50 references, click to expand
  1. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.
    Nat Med. 1999 Nov;5(11):1270-6 PMID: 10545993
  2. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.
    J Virol. 1999 Aug;73(8):6715-20 PMID: 10400769
  3. Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site.
    J Immunol. 2000 Feb 15;164(4):1898-905 PMID: 10657639
  4. Antigen recognition.
    Curr Opin Immunol. 2000 Feb;12(1):77-9 PMID: 10712002
  5. MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells.
    J Immunol. 2000 May 1;164(9):4500-6 PMID: 10779750
  6. Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay.
    J Virol. 2000 Sep;74(18):8541-9 PMID: 10954555
  7. Emerging genetic diversity of HIV-1 in South America.
    AIDS. 2000 Aug 18;14(12):1785-91 PMID: 10985316
  8. Viral escape and the failure of cellular immune responses.
    Science. 2000 Sep 22;289(5487):2003 PMID: 11032545
  9. AIDS. Escape from the immune system.
    Nature. 2000 Sep 21;407(6802):313-4 PMID: 11014174
  10. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.
    Nature. 2000 Sep 21;407(6802):386-90 PMID: 11014195
  11. Immune control of HIV-1 after early treatment of acute infection.
    Nature. 2000 Sep 28;407(6803):523-6 PMID: 11029005
  12. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
    Science. 2000 Oct 20;290(5491):486-92 PMID: 11039923
  13. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children.
    J Exp Med. 2000 Dec 18;192(12):1819-32 PMID: 11120778
  14. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.
    J Exp Med. 2001 Jan 15;193(2):169-80 PMID: 11148221
  15. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals.
    Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1781-6 PMID: 11172028
  16. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
    Science. 2001 Apr 6;292(5514):69-74 PMID: 11393868
  17. Immune control of HIV: the obstacles of HLA and viral diversity.
    Nat Immunol. 2001 Jun;2(6):473-5 PMID: 11376327
  18. Evolution and transmission of stable CTL escape mutations in HIV infection.
    Nature. 2001 Jul 19;412(6844):334-8 PMID: 11460164
  19. Vpr is preferentially targeted by CTL during HIV-1 infection.
    J Immunol. 2001 Sep 1;167(5):2743-52 PMID: 11509618
  20. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design.
    J Virol. 2001 Oct;75(19):9210-28 PMID: 11533184
  21. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection.
    J Virol. 2001 Dec;75(24):11983-91 PMID: 11711588
  22. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.
    Nature. 2002 Jan 17;415(6869):335-9 PMID: 11797012
  23. HIV-1 Vpu represents a minor target for cytotoxic T lymphocytes in HIV-1-infection.
    AIDS. 2002 May 3;16(7):1071-3 PMID: 11953475
  24. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection.
    Nat Med. 2002 May;8(5):493-9 PMID: 11984594
  25. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level.
    Science. 2002 May 24;296(5572):1439-43 PMID: 12029127
  26. Diversity considerations in HIV-1 vaccine selection.
    Science. 2002 Jun 28;296(5577):2354-60 PMID: 12089434
  27. HIV: current opinion in escapology.
    Curr Opin Microbiol. 2002 Aug;5(4):408-13 PMID: 12160861
  28. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection.
    J Virol. 2002 Sep;76(17):8690-701 PMID: 12163589
  29. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation.
    J Virol. 2002 Sep;76(17):8757-68 PMID: 12163596
  30. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.
    J Virol. 2002 Oct;76(20):10155-68 PMID: 12239290
  31. Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS.
    J Virol. 2002 Nov;76(21):10674-84 PMID: 12368309
  32. The functional CD8 T cell response to HIV becomes type-specific in progressive disease.
    J Clin Invest. 2002 Nov;110(9):1339-47 PMID: 12417573
  33. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus.
    Nature. 2002 Nov 28;420(6914):434-9 PMID: 12459786
  34. Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection.
    J Virol. 2003 Jan;77(2):882-90 PMID: 12502804
  35. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.
    J Virol. 2003 Feb;77(3):2081-92 PMID: 12525643
  36. Chemistry of peptide interactions with MHC proteins.
    Curr Opin Immunol. 1992 Feb;4(1):79-86 PMID: 1596372
  37. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
    J Virol. 1994 Jul;68(7):4650-5 PMID: 8207839
  38. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.
    J Virol. 1994 Sep;68(9):6103-10 PMID: 8057491
  39. MHC ligands and peptide motifs: first listing.
    Immunogenetics. 1995;41(4):178-228 PMID: 7890324
  40. Protecting HIV databases.
    Nature. 1995 Nov 16;378(6554):242-4 PMID: 7477340
  41. Maintaining the integrity of human immunodeficiency virus sequence databases.
    J Virol. 1996 Aug;70(8):5720-30 PMID: 8764096
  42. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.
    Nat Med. 1997 Feb;3(2):205-11 PMID: 9018240
  43. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.
    Nat Med. 1997 Feb;3(2):212-7 PMID: 9018241
  44. Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses.
    J Virol. 1997 Jun;71(6):4284-95 PMID: 9151816
  45. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.
    Science. 1998 Mar 27;279(5359):2103-6 PMID: 9516110
  46. Dendritic cells transfected with the nef genes of HIV-1 primary isolates specifically activate cytotoxic T lymphocytes from seropositive subjects.
    Eur J Immunol. 1999 Jan;29(1):196-202 PMID: 9933101
  47. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
    Science. 1999 Feb 5;283(5403):857-60 PMID: 9933172
  48. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.
    J Exp Med. 1999 Mar 15;189(6):991-8 PMID: 10075982
  49. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression.
    Nat Med. 1999 May;5(5):518-25 PMID: 10229228
  50. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.
    J Virol. 1999 Dec;73(12):10489-502 PMID: 10559367
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2003-07-00
Pages
7330-40
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC164796
Subset
IM
Grants
NIAID NIH HHS · R37 AI128568 · United States
NIAID NIH HHS · R01 AI040873 · United States
NIAID NIH HHS · R01 AI44656 · United States
NIAID NIH HHS · R01 AI30914 · United States
NIAID NIH HHS · R01 AI50429 · United States
NIAID NIH HHS · U01 AI41531 · United States
NIAID NIH HHS · R01 AI40873 · United States
NIAID NIH HHS · R01 AI050429 · United States
NIAID NIH HHS · U01 AI041531 · United States
NIAID NIH HHS · R01 AI044656 · United States
NIAID NIH HHS · U01 AI41535 · United States
NIAID NIH HHS · R01 AI030914 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com